Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VisgeneerROCO:4197 +9.22%54 EBITDA Margin % is 11.46% as of Dec. 2025, which is 91% above its 10-year median of 5.99. GuruFocus rates ROCO:4197 with a GF Score™ of 54/100 and a GF Value™ of NT$13.80 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Visgeneer ranks better than 75.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Visgeneer's EBITDA for the
six
months ended in Dec. 2025 was NT$10.2 Mil. Visgeneer's Revenue for the
six
months ended in Dec. 2025 was NT$89.1 Mil. Therefore, Visgeneer's EBITDA margin for the quarter that ended in Dec. 2025 was 11.46%.
Visgeneer (ROCO:4197) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Visgeneer EBITDA Margin % Related Terms
Visgeneer EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Visgeneer's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4197 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Visgeneer's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Visgeneer EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Visgeneer's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Visgeneer's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Visgeneer (ROCO:4197) has a EBITDA Margin % of 11.46% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Visgeneer and its competitors. This is 91% above median its historical median of 5.99. According to the industry distribution chart, Visgeneer ranks #226 out of 939 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Visgeneer's EBITDA Margin % too high?
Visgeneer's current EBITDA Margin % of 11.46% is 91% above median its 10-year median of 5.99. Based on the distribution chart, Visgeneer ranks #226 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Visgeneer has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Visgeneer's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Visgeneer ranks #226 out of 939 companies for EBITDA Margin %. This places Visgeneer in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Visgeneer and its competitors. Visgeneer's current EBITDA Margin % is 11.46%, which is 91% above median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Visgeneer stock overvalued right now?
Based on GuruFocus' analysis, Visgeneer (ROCO:4197) is currently considered Possible Value Trap. The stock's GF Value™ is NT$13.80, compared to a current price of NT$9.48 — trading 31.3% below its estimated fair value. The current EBITDA Margin % is 11.46%, which is 91% above median its 10-year median of 5.99. Visgeneer's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Visgeneer (ROCO:4197), the current EBITDA Margin % is 11.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Visgeneer (ROCO:4197) Overvalued in 2026?
Based on GuruFocus' analysis, Visgeneer stock appears to be undervalued.
The current stock price of NT$9.48 is trading 31.3% below its estimated GF Value™ of NT$13.80.
GuruFocus considers Visgeneer to be Possible Value Trap.
Key valuation signals for ROCO:4197:
EBITDA Margin %: 11.46% (91% above median its 10-year median of 5.99)
GF Value™: NT$13.80 vs. price of NT$9.48 (31.3% below fair value)
No single metric tells the full story. See the ROCO:4197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Visgeneer Inc is a Taiwan based Biotech company involved in developing and, manufacturing biomedical products in the areas of Bacterial Fermentation, Medical Device, Cosmetics/Skin Care, and Cancer Gene identification. Its products include Blood Glucose and Ketone Monitoring System, Ginkgo Biloba series, Peptide-Complex series, Hyaluronic Acid Essence Series and High-Quality Masks among others.
54GF Score
Get the complete analysis for ROCO:4197
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4197 has been successfully added to your 
